Transcenta to Present Updated Results of Cohort G from a Phase I/IIa Study of First-line Osemitamab (TST001) plus Nivolumab and CAPOX for Advanced G/GEJ Cancer at ASCO 2025

AACR 2025 | Transcenta to Debut Preclinical Data of a Novel FGFR2b-targeting ADC

Transcenta to Present I/IIa Study Results of First-line Osemitamab (TST001) plus Nivolumab and CAPOX for Advanced G/GEJ Cancer at ASCO 2024

Transcenta to Present Osemitamab (TST001) and TST003 Study Results at AACR 2024

Transcenta 2023 R&D Day

Transcenta's CEO, Dr. Xueming Qian will be participating in Turning Science Into Business Submit: Cancer research opportunities and advances.